Skip to main content
. Author manuscript; available in PMC: 2021 Jan 15.
Published in final edited form as: Clin Cancer Res. 2020 Apr 22;26(14):3707–3719. doi: 10.1158/1078-0432.CCR-20-0269

Fig. 5. AMPK activation via metformin promotes survival of ER+ BC cells following estrogen withdrawal.

Fig. 5.

(A) Cells were treated with HD ±1 mM metformin. Relative viable cell numbers after 21–28 d were compared to control by t-test (*p≤0.05). (B) siRNA-transfected cells were treated for 7 d then analyzed as in (A). *p≤0.05 by Bonferroni multiple comparison-adjusted posthoc test. n.s.-not significant. In (A/B), data are presented as mean of triplicates +SD. (C) Schematic of experiment performed in (D). Ovx mice with E2-driven tumors (400 mm3) were treated with EW ± metformin (~5 mg/d via drinking water) for 90 d. Tumor volumes were monitored by caliper measurements. (D) Proportions of tumors that completely regressed over time were compared by log-rank test. (E) Tumors harvested from mice after 12 d (MCF-7) or 6 d (HCI-017, HCC-1428) of treatment with EW ± metformin were analyzed by IHC for P-ACCSer79. *t-test p≤0.05.